Overview

Tapering Heart Failure Medication in Patients with Heart Failure with Recovered Ejection Fraction; Open Label Prospective Random Trial

Status:
NOT_YET_RECRUITING

Trial end date:
2027-11-26

Target enrollment:

Participant gender:

Summary

Study start date is on Nov 27th 2024. A patient with an initial ejection fraction (EF) of less than 40%, whose follow-up shows an improvement to an EF of 50% or higher, along with the left ventricular end-diastolic diameter returning to the normal range and taking 3 more heart failure medication randomed to drug tapering group ( RAS blocker or beta blocker) or continuing medication group.

Phase:

Details

Lead Sponsor:

Chungnam National University Hospital